- Home
- Publications
- Publication Search
- Publication Details
Title
Sulbactam/Durlobactam: First Approval
Authors
Keywords
-
Journal
DRUGS
Volume 83, Issue 13, Pages 1245-1252
Publisher
Springer Science and Business Media LLC
Online
2023-07-31
DOI
10.1007/s40265-023-01920-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections
- (2023) Richard R Watkins et al. CLINICAL INFECTIOUS DISEASES
- The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex
- (2023) John P O’Donnell et al. CLINICAL INFECTIOUS DISEASES
- Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex
- (2023) Mariana Castanheira et al. CLINICAL INFECTIOUS DISEASES
- Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections
- (2023) Ryan K Shields et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)
- (2023) Keith S Kaye et al. LANCET INFECTIOUS DISEASES
- Sulbactam‐durlobactam: A novel β‐lactam‐β‐lactamase inhibitor combination targeting carbapenem‐resistant Acinetobacter baumannii infections
- (2023) Amer El‐Ghali et al. PHARMACOTHERAPY
- In-vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance
- (2022) Jacqueline Findlay et al. Journal of Global Antimicrobial Resistance
- In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii - calcoaceticus Complex Collected from 2016 to 2021
- (2022) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A randomized, double‐blind, placebo‐ and positive‐controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects
- (2021) John O’Donnell et al. CTS-Clinical and Translational Science
- Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam
- (2021) Adam B. Shapiro et al. Frontiers in Microbiology
- Safety, Pharmacokinetics, and Drug:Drug Interaction Potential of Intravenous Durlobactam, a β-lactamase Inhibitor, in Healthy Subjects
- (2020) Jason D. Lickliter et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China
- (2020) Qiwen Yang et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii
- (2020) Harald Seifert et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Acinetobacter baumannii Resistance: A Real Challenge for Clinicians
- (2020) Rosalino Vázquez-López et al. Antibiotics-Basel
- Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent
- (2019) Melissa D. Barnes et al. mBio
- Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
- (2019) Olexiy Sagan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects
- (2018) Keith A. Rodvold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
- (2017) Thomas F. Durand-Réville et al. Nature Microbiology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More